News & Updates

Add-on acalabrutinib prolongs PFS in older patients with untreated MCL
Add-on acalabrutinib prolongs PFS in older patients with untreated MCL
04 Sep 2024 byAudrey Abella

In older patients with untreated mantle cell lymphoma (MCL), the addition of the Bruton tyrosine kinase (BTK) inhibitor acalabrutinib to bendamustine and rituximab (ABR) conferred a statistically significant and clinically meaningful improvement in progression-free survival (PFS) with a favourable trend for overall survival (OS), findings from the phase III ECHO trial have shown.

Add-on acalabrutinib prolongs PFS in older patients with untreated MCL
04 Sep 2024
Bipolar disorder roadmap: Navigating warning signs from childhood to adolescence in offspring of patients
Bipolar disorder roadmap: Navigating warning signs from childhood to adolescence in offspring of patients
03 Sep 2024 byKanas Chan

Behavioural problems during childhood, along with delayed circadian rhythm, social anxiety, and mood symptoms in adolescence, may serve as early indicators of bipolar disorder in offspring of Chinese parents with the disorder, a case-control high-risk offspring study has shown.

Bipolar disorder roadmap: Navigating warning signs from childhood to adolescence in offspring of patients
03 Sep 2024